Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: A Nordic multicenter study

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 8-9, 2012, Pages 1021-1029

  Jorgensen, Kristin Kaasen ^a,b,c   Lindström, Lina ^d   Cvancarova, Milada ^b   Castedal, Maria ^e   Friman, Styrbjörn ^e   Schrumpf, Erik ^a,b,c   Foss, Aksel ^b,c   Isoniemi, Helena ^b   Nordin, Arno ^b   Holte, Kathrine ^f   Rasmussen, Allan ^f   Bergquist, Annika ^d   Vatn, Morten H ^a,c,g   Boberg, Kirsten Muri ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aminosalicylates; Colorectal cancer; Inflammatory bowel disease; Ursodeoxycholic acid

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CHILD; CLINICAL ASSESSMENT; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORWAY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84865702699     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.685754     Document Type: Article

References (36)

1. Available from www.scandiatransplant.org.
2. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11: 31-9.
3. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholan-gitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10: 430-6.
4. Jørgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012;18: 536-45.
5. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48: 526-35.
6. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22: 1404-8.
7. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50: 158-64.
8. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94: 1643-9.
9. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56: 48-54.
10. Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008;14: 3497-503.
11. Loftus EV Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenter-ology 1996;110: 432-40.
12. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer 1998;82: 822-6.
13. Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006;26: 31-41.
14. Loftus EV Jr, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998;27: 685-90.
15. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993;36: 908-12.
16. Dvorchik I, Subotin M, Demetris AJ, Fung JJ, Starzl TE, Wieand S, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cho-langitis. Hepatology 2002;35: 380-4.
17. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21: 870-7.
18. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14: 931-68.
19. Lindström L, Lapidus A, Ost A, Bergquist A. Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum 2011;54: 1392-7.
20. Pintilie M. Competing risks. A practical perspective. Chi-chester, West Sussex: John Wiley & sons, Ltd; 2006.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
22. Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003;75: 1983-8.
23. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323: 1228-33.
24. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicy-late use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100: 1345-53.
25. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, et al. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008;2: 63-92.
26. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011;106: 731-6.
27. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126: 451-9.
28. Tang J, Sharif O, Pai C, Silverman AL. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 2010;55: 1696-703.
29. Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001;44: 77-85.
30. Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012;18: 269-74.
31. Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2: 240.
32. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134: 89-95.
33. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124: 889-93.
34. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxy-cholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;22: 783-8.
35. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. Am J Gastroenterol 2011;106: 1638-45.
36. Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009;15: 1331-6.